ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 1000 iu - coagulation factor viii

ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii

ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii

ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

ישראל - עברית - Ministry of Health

novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.